## By Speed Post/Online



## F.No. J-11011/359/2008- IA II(I) Government of India Ministry of Environment, Forest and Climate Change (Impact Assessment Division)

\*\*\*

Indira Paryavaran Bhawan Jorbagh Road, New Delhi - 110003

Dated: 13th October, 2020

To,

M/s Ajanta pharma Ltd

Gut No.378, Plot No. 8 Aurangabad -Pune Highway Village Waluj, Taluka Gangapur District Aurangabad, Maharashtra - 431133

Email: gopal.rathi@ajantapharma.com

Sub: Increasing the number of active pharmaceutical ingredients (API) products from 85 to 258 within the total production capacity of 21.042 TPM at Gut No.378, Plot No. 8, Aurangabad -Pune Highway, Village Waluj, Taluka Gangapur, District Aurangabad, Maharashtra by M/s Ajanta pharma Ltd -Environmental Clearance - regarding

Sir,

This has reference to your proposal No. IA/MH/IND2/125305/2008 dated 3<sup>rd</sup> July, 2020, submitting the EIA/EMP report on the above subject matter.

- 2. The Ministry of Environment, Forest and Climate Change has examined the proposal for Environmental Clearance to the project for Increasing the number of active pharmaceutical ingredients (API) products from 85 to 258 within the total production capacity of 21.042 TPM by M/s Ajanta pharma Ltd, in an area of 3200.5 sqm., located at Gut No.378, Plot No. 8, Aurangabad-Pune Highway, Village Waluj, Taluka Gangapur, District Aurangabad, Maharashtra.
- **3.** The details of products and capacity are as under:

S. No.	Product	Existing	Proposed	Total	
		ТРМ			
1	Lumefantrine	2.5	-2.5	0	
2	Artemether ·				
3	Nepafenac	2.8	-1.2 1.6	1.6	
4	Loteprednol Etabonate				
5	Bromfenac Sodium				
6	Prednisolone Acetate				
7	Tafluprost				
8	Iguratimod				
9	Desonide 21 - Phosphate				
10	Levobetaxolol HCI				
11	Apremilast				
/12/	Difluprednate				

QEC for M/s Ajanta pharma Ltd

Page 1 of 13

13	Mesalamine			
14	Nimesulide			
15	Indomethacin			
16	Meclofenamate Sodium			
17	Fenspiride Chlorhydrate			
18	Fluorometholone acetate			
19	Roflumilast			
20	Mometasone Furoate			
	Monohydrate			
21	Crisaborole	0	0.8	0.8
22	Polmacoxib			
23	Piclidenoson			
24	Lifitegrast			
25	Betaxolol HCL			
26	Cyclosporine			
27	Dexamethasone			
28	Propyphenazone			
29	Dimethyl Fumarate			
30	Triamcinolone			
31	Apabetalone			
32	Amtolmetin Guacil	1.1	-0.4	0.7
33	Naproxcinod			
34	Neramaxane Mesylate			
35	Tofacitinib Citrate			
36	Nadifloxacin			
37	Zucapsaicin			
38	Nalbuphine Sebacate	0	0.2	0.2
39	Sufentanil Citrate			13-
40	Penicillamine	0	0.4	0.4
41	Hydroxychloroquine			\$50.500 st
42	Baricitinib			
43	Benvitimod			
44	Ilaprazole	1.2	-0.6	0.6
45	Lansoprazole Sodium			
46	Lafutidine			
47	Dexlansoprazole	0	0.2	0.2
48	Omeprazole Sodium			
49	Tegoprazan			
50	Diquafosol Tetrasodium			
51	Omidenepag Isopropyl	0	0.1	0.1
52	Metaxalone	0	0.05	0.05
53	Rebamipide	0.2	-0.1	0.1
54	Linaclotide	0	0.1	0.1
55	Elobixibat			
56	Nitroglycerin	0	0.05	0.05
57	Olopatadine HCL	0.452	-0.12	0.332
58	Bilastine			
59	Bepotastine Besilate			
60	Tacalcitol MH			
61	Palonosetron HCL		No. of the last of	
New Mile I		41		

62	Flupirtine Maleate			
63	Cetilistat	0	0.1	
64	Silodosin	0.1	0	0.1
65	Fexapotide	0	0.1	0.1
66	Mirabegron	0	0.1	0.1
67	Colestipol HCL	0	0.1	0.1
68	Aripiprazole	0.2	0	0.2
69	Olanzapine	0	0.05	0.05
70	Ropinirol HCl	0	0.1	0.1
71	Latanoprost	0.12	0	0.12
72	Brinzolamide			0.11
73	Bimatoprost			
74	Ripasudil Hydrochloride	0	0.38	0.38
3 181	Hydrate			2,24
75	Limaprost			
76	Netarsudil			
77	Latanoprostene Bunod			
78	Travoprost			
79	Brimonidine Tartrate			
80	Tavilermide			
81	Glycerol	0	0.05	0.05
82	Cortexolone 17a- Propionate	0	0.05	0.05
83	Vilanterol trifenatate	0	0.05	0.05
84	Rolapitant	0	0.05	0.05
85	Varenicline Tartrate	0	0.05	0.05
86	Ulipristal Acetate	0	0.05	0.05
87	Dabigatran Etexilate	0.1	0	0.1
	Mesylate		1947.00	500 may 200 mg 2
88	Rivaroxaban	0	0.6	0.6
89	Edoxaban			
90	Betrixaban			
91	Pentosan Polysulfate			
92	Elinogrel			
93	Divalproex Sodium	0	0.05	0.05
94	Ursodiol	0.01	0	0.01
95	Raltegravir Potassium	0	0.35	0.35
96	Maraviroc			
97	Daclatasvir Dihydrochloride			
98	Valganciclovir			
99	Simeprevir			
100	Gemifloxacin Mesylate	0.9	-0.25	0.65
101	Minocycline HCL			
102	Besifloxacin HCL			
103	Retapamulin			
104	Sodium hyaluronate			
105	N-acetyl-L-carnosine			2451
106	Ospemifene	0	1	1
107	Ozenoxacin			
108	Solithromycin			
109	Erythromycin Ethyl		1	

-				
110	Moxifloxacin HCL			
111	Tobramycin			
112	Rifaximin			
113	Doxycycline Hyclate			
114	Doxycycline Monohydrate			
115	Levofloxacin Hemihydrate			
116	Sarecycline			
117	Nemonoxacin			
118	Flucloxacillin Sodium			
119	Amadacycline			
120	Omadacycline			
121	Finafloxacin hydrochloride			
122	Cethromycin			
123	Almotriptan	0	1	1
124	Sumatriptan			
125	Frovatriptan Succinate			
126	Lasmiditan			
127	Eletriptan HBr			
128	Zolmitriptan			
129	Rimegepant			
130	Sevelamer Carbonate			
131	Aclidinium Bromide	2.51	-1.1	1.41
132	Solifenacin Succinate			
133	Azelnidipine			
134	Cilnidipine			
135	Azilsartan Medoxomil			
	Potassium			
136	Metoprolol succinate			
137	Fimasartan Potassium			
	Trihydrate			
138	Rosuvastatin calcium			
139	Efonidipine Hydrochloride			
	Ethanolate			
140	Olmesartan			1
141	Perindopril Arginine			
142	Phentermine Hydrochloride	0	0.8	8.0
143	Sacubitril			
144	Nifedipine			
145	Chlorthalidone			
146	Diltiazem Hydrochloride			
147	Telmisartan			
148	Timolol maleate			
149	Dalcetrapib			
150	Valsartan			
151	Ambrisentan			
152	Sacubitril-Valsartan			
153	Sacubitril-Telmisartan			
154	Polaprezinc	0	0.05	0.05
155	Bempedoic Acid	0	0.05	0.05
156	Cholestyramine			

157	Ivabradine HCL	0.2	-0.1	0.1
158	Delmopinol Hydrochloride	0	0.1	0.1
159	Octinidine HCL			
160	Bibrocathol			
161	Lanthanum Carbonate	0	0.05	0.05
162	Asenapine Maleate	0	0.1	0.1
163	Clozapine			
164	Propafenone HCL	0	0.05	0.05
165	Deferasirox	0.1	-0.05	0.05
166	Trientine Hydrochloride	0	0.05	0.05
167	Cinacalcet HCl	0	0.03	0.03
168	Tavaborole	0.5	-0.1	0.4
169	Efinaconazole			
170	Luliconazole			
171	Fenticonazole Nitrate	0	0.2	0.2
172	Flucytosine			
173	Voriconazole			
174	Bremelanotide			
175	Topiroxostat			
176	L- Methyl folate	0.2	-0.1	0.1
5241 90 9-511	Glucosamine	A 12-0-		15500
177	Odanacatib	0	0.02	0.02
178	Sapropterin	0	0.04	0.04
	Dihydrochloride			
179	Dendrimer	0	0.05	0.05
180	Colesevelam HCL	1.2	-0.3	0.9
181	Teneligliptin Hydrobromide			
	Hydrate			
182	Sitagliptin Phosphate			
183	Alogliptin			
184	Vildagliptin			
185	Linagliptin			
186	Chiglitazar			
187	Canagliflozin Hemihydrate	0	1.2	1.2
188	Dapagliflozin Propanediol			
	Monohydrate			
189	Anagliptin			
190	Trelagliptin Succinate			
191	Empagliflozin			
192	Ipragliflozin			
193	Saxagliptin			
194	Mirogabalin			
195	Sotagliflozin			
196	Canagliflozin Propagadiol			
197	Dapagliflozin Propanediol			
198	Dapagliflozin			
199	Lucasificzia			
200	Luseogliflozin			
201	Tofogliflozin	_		
202,	Gemigliptin			

203	Evogliptin			
204	Emixustat Hcl			
205	Retagliptin Phosphate			
206	Ertugliflozin			
207	Omarigliptin			
208	Semaglutide			
209	Vardenafil HCL Trihydrate	2.7	-2	0.7
210	Sildenafil citrate Mask	0	0.3	0.3
210	Complex		0.5	0.3
211	Mirodenafil			
212	Sildenafil citrate			
213	Tadalafil			
214	Dapoxetine HCL	0.2	-0.1	0.1
215	Ticagrelor	0.2	0.05	0.05
216	Voclosporin		0.03	0.03
217	Alcaftadine	0.1	0	0.1
218	Azelastine HCL	0.1	0.1	0.1
219	Cloperastine Fendizoate		0.1	0.1
220	Acotiamide Hydrochloride	0.2	0	0.3
220	Hydrate	0.2	U	0.5
221	Obeticholic Acid	0	0.05	0.05
222	Ibrutinib	0	0.05	0.05
223	Pirfenidone	0	0.05	0.05
224	Vortioxetine HBr	0	0.05	0.05
225	Hypochlorous Acid	0	0.03	0.05
226				U
227	Apixaban Dienogest	0	0.05	0.05
228	Carboxymethyl cellulose	0	0.05	0.05
220	Sodium	0	0.05	0.05
229	Hydroquinone	0	0.05	0.05
230	Pyridoxine HCL	0	0.05	0.05
231	Ivacaftor	0	0.05	0.05
232	Febuxostat	1.5	-1.3	7-12-12-12-12-12-12-12-12-12-12-12-12-12-
233	Lesinurad	0	0.1	0.2
234		0	0.05	
235	Netupitant Indacaterol Maleate	0		0.05
		0	0.05	0.05
236	Vilazodone Hydrochlorida	U	0.1	0.1
237	Duloxetine Hydrochloride	0	0.05	0.05
238	Potassium Citrate Alosetron HCL	0	0.05	0.05
240	Tizanidine HCL	0	0.05	0.05
240	Isosorbide Mononitrate	0	0.05	0.05
		0.40	0.07	0.07
242	Entacapone Cytiding-F'-disodium	0.2	-0.15	0.05
243	Cytidine-5'-disodium monophosphate	U	0.1	0.1
244				
244	Uridine Diphosphate	0	0.1	0.1
245	Phloroglucinol Dihydrate	U	0.1	0.1
246	Trimethyl Phloroglucinol Spironolactone		0.07	0.07
	Triamcinolone Acetonide	0	0.07	0.07
248	Thamcinoione Acetonide	U	0.07	0.07

	Total		21.042	
	purpose			
258	R&D Project for study	0	0.3	0.3
257	Montelukast Sodium	0.2	0	0.2
256	Clopidogrel Bisulfate	0.5	-0.2	0.3
255	Picotamide	1	-0.6	0.4
254	Nolasiban	0	0.05	0.05
253	Olumacostat Glasaretil	0	0.06	0.06
252	Vilaprisan	0	0.05	0.05
251	Finerenone	0	0.05	0.05
250	Suvorexant	0	0.08	0.08
249	Vadadustat	0	0.05	0.05

- 4. The existing land area is 3200.5 sqm. No additional land is required for the proposed expansion. Industry has already developed greenbelt in an area of 790 sqm. In addition, 1 acre of private land adjacent to the project site has also been developed as greenbelt. The estimated project cost is Rs 1.5 crores and the existing investment is Rs 13.40 crores. Total capital cost earmarked towards environmental pollution control measures including for the existing unit is Rs. 1.737 crores and the recurring cost (O&M) will be about Rs.0.565 crores per annum. The project will provide employment for 10-15 persons directly in the proposed project.
- **5.** There are no National parks, Wildlife sanctuaries, Biosphere Reserves, Tiger/Elephant Reserves, Wild life Corridors etc. within 10 km distance from the project site. Kham river (1.4km East), Nagjhari river (6.6km West), Kohli Nallah (8.9km South) and Jogeshwari Talav (1.8km North West) are located within 10 km from the project site.
- **6.** Total water requirement is estimated to be 82.2 cum/day, which includes fresh water requirement of 60 cum/day, proposed to be met from MIDC Waluj water supply. Effluent of 20.2 cum/day will be treated through 25 KLD ETP. Industry proposed to install RO followed by Evaporator System. There will be no discharge of treated/untreated waste water from the unit, and thus ensuring Zero Liquid Discharge.

There is no additional power requirement. Existing power requirement is 450 kW and connected load is 720 kW, which is sourced from MSEDCL. Existing unit has 1 DG set of 400 kVA capacity and additionally, 100 kVA DG set shall be installed for utilization during power failure. Stack (height 4.5m) will be provided as per CPCB norms to the DG sets. Existing unit has 850 kg/hr diesel boiler and no additional boiler is proposed.

The process/fugitive emission are scrubbed with the help of Venturi Scrubber. The same scrubber shall be used for control of process/ fugitive emission arising due to the proposed expansion. Ammonia sensor is installed within the plant area to raise alarm situation if ammonia level increases beyond permissible limit. Process emission contains solvent only and shall recovered. Monthly work zone & ambient air quality monitoring will be carried out to ensure quality index of air.

- **7.** The project/activities are covered under category A of 5(f) 'Synthetic organic chemicals industry' of the Schedule to the Environment Impact Assessment Notification, 2006, and requires appraisal at central level by the sectoral Expert Appraisal Committee (EAC) in the Ministry.
- 8. Standard Terms of References (ToR) has been issued by the Ministry vide letter

TEC for M/s Ajanta pharma Ltd

Page 7 of 13

dated 11<sup>th</sup> March 2018. Public hearing for the project has been conducted by the State Pollution Control Board on 14<sup>th</sup> June, 2019, which was presided over by the District Magistrate. The main issues raised during the public hearing are related to additional air pollution load, green belt development, employment, reactions in the process, water pollution, water conservation and socio economic status, etc.

- **9.** The Ministry has earlier issued environmental clearance (EC) vide letter dated 10<sup>th</sup> June 2009 to the existing project for Active pharmaceutical ingredients (API) Industry in favour of M/s Ajanta Pharma Ltd. Certified compliance report on the existing EC has been forwarded by the Ministry's Regional Nagpur vide letter dated 28<sup>th</sup> January, 2019. It was informed by the project proponent that there is no litigation pending against the proposal.
- **10.** The proposal was considered by the Expert Appraisal Committee (Industry-2) in its meeting held on 17-19 August, 2020 in the Ministry, wherein the project proponent and their accredited consultant M/s Building Environment (India) Pvt Ltd presented the EIA/EMP report as per the ToR. The Committee found the EIA/EMP report complying with the ToR and recommended the project for grant of environmental clearance.
- **11.** The EAC, constituted under the provision of the EIA Notification, 2006 and comprising of Experts Members/domain experts in various fields, have examined the proposal submitted by the Project Proponent in desired form along with EIA/EMP report prepared and submitted by the Consultant accredited by the QCI/ NABET on behalf of the Project Proponent.

The EAC noted that the Project Proponent has given undertaking that the data and information given in the application and enclosures are true to the best of his knowledge and belief and no information has been suppressed in the EIA/EMP report. If any part of data/information submitted is found to be false/ misleading at any stage, the project will be rejected and Environmental Clearance given, if any, will be revoked at the risk and cost of the project proponent.

The Committee noted that the EIA/EMP report is in compliance of the ToR issued for the project, reflecting the present environmental concerns and the projected scenario for all the environmental components. The Committee has found the baseline data and incremental GLC due to the proposed project within NAAQ standards. The Committee has also deliberated on the public hearing issues, action plan and the CER plan and found to be addressing the issues in the study area. The Committee noted that the project site is located in the Severely Polluted Area and opined that the CER amount shall be fixed at 2% of the project as per the Ministry's OM and guidelines on CPA/SPA. Certified report on compliance of existing EC conditions also found to be satisfactory.

The EAC has deliberated the proposal and has made due diligence in the process as notified under the provisions of the EIA Notification, 2006, as amended from time to time and accordingly made the recommendations to the proposal. The Experts Members of the EAC have found the proposal in order and have recommended for grant of environmental clearance.

12. The environmental clearance granted to the project/activity is strictly under the provisions of the EIA Notification 2006 and its amendments. It does not tantamount/construe to approvals/consent/ permissions etc. required to be obtained or standards/conditions to be followed under any other Acts/ Rules/ Subordinate legislations, etc., as may be applicable to the project. The project proponent shall obtain necessary permission as mandated under the Water (Prevention and Control of Pollution) Act, 1974 and the Air (Prevention and Control of Pollution) Act, 1981, as applicable from time to

CEC for M/s Ajanta pharma Ltd

time, from the State Pollution Control Board, prior to construction & operation of the project.

- 13. Based on the proposal submitted by the project proponent and recommendations of the EAC (Industry-2), Ministry of Environment, Forest and Climate change hereby accords environmental clearance to the project for Increasing the number of active pharmaceutical ingredients (API) products from 85 to 258 within the total production capacity of 21.042 TPM by M/s Ajanta pharma Ltd at Gut No.378, Plot No. 8, Aurangabad-Pune Highway, Village Waluj, Taluka Gangapur, District Aurangabad, Maharashtra, under the provisions of the EIA Notification, 2006, subject to the compliance of terms and conditions as under:-
- (i) The SPCB shall follow the mechanism/protocol issued by the Ministry vide letter no. Q-16017/38/2018-CPA dated 24<sup>th</sup> October, 2019 and forwarded by Central Pollution Control Board vide letter dated 25<sup>th</sup> October, 2019 to the SPCB's, while issuing the CTE/CTO for the project, for improvement of environmental quality in the area.
- (ii) The company shall comply with all the environmental protection measures and safeguards proposed in the documents submitted to the Ministry. All the recommendations made in the EIA/EMP in respect of environmental management, and risk mitigation measures relating to the project shall be implemented.
- (iii) Fugitive emissions shall be controlled at 99.98% with effective chillers. Volatile organic compounds (VOCs)/Fugitive emissions shall be controlled at 99.997% with effective chillers/modern technology.
- (iv) As already committed by the project proponent, Zero Liquid Discharge shall be ensured and no waste/treated water shall be discharged outside the premises. Treated effluent shall be reused in the process/utilities. Treated Industrial effluent shall not be used for gardening/greenbelt development/horticulture.
- (v) Effluent/residue of API/drugs shall not be allowed to mix with the waste water.
- (vi) Occupational health centre for surveillance of the worker's health shall be set up. The health data shall be used in deploying the duties of the workers. All workers & employees shall be provided with required safety kits/mask for personal protection.
- (vii) The unit shall make the arrangement for protection of possible fire hazards during manufacturing process in material handling. Fire-fighting system shall be as per the norms.
- (viii) Training shall be imparted to all employees on safety and health aspects of chemicals handling. Safety and visual reality training shall be provided to employees.
- (ix) Total fresh water requirement shall not exceed 60 cum/day, proposed to be met from MIDC water supply. Prior permission in this regard shall be obtained from the concerned regulatory authority.
- (x) Process effluent/any wastewater shall not be allowed to mix with storm water. The storm water from the premises shall be collected and discharged through a separate conveyance system. All the vent pipes should be above the roof level.

Co for M/s Ajanta pharma Ltd

- (xi) Continuous online (24x7) monitoring system for stack emissions shall be installed for measurement of flue gas discharge and the pollutants concentration, and the data to be transmitted to the CPCB and SPCB server. For ZLD, the unit shall install web camera with night vision capability and flow meters in the channel/drain carrying effluent within the premises.
- (xii) Solvent management shall be carried out as follows: (a) Reactor shall be connected to chilled brine condenser system. (b) Reactor and solvent handling pump shall have mechanical seals to prevent leakages. (c) Solvents shall be stored in a separate space specified with all safety measures. (d) Proper earthing shall be provided in all the electrical equipment wherever solvent handling is done. (e) Entire plant shall be flame proof. The solvent storage tanks shall be provided with breather valve to prevent losses. (f) All the solvent storage tanks shall be connected with vent condensers with chilled brine circulation.
- (xiii) Process organic residue and spent carbon, if any, shall be sent to Cement other suitable industries for its incinerations. ETP sludge, process inorganic & evaporation salt shall be disposed of to the TSDF.
- (xiv) The company shall undertake waste minimization measures as below (a) Metering and control of quantities of active ingredients to minimize waste; (b) Reuse of byproducts from the process as raw materials or as raw material substitutes in other processes. (c) Use of automated filling to minimize spillage. (d) Use of Close Feed system into batch reactors. (e) Venting equipment through vapour recovery system. (f) Use of high pressure hoses for equipment clearing to reduce wastewater generation.
- (xv) The green belt of at least 5-10 m width shall be developed in nearly 33% of the total project area, mainly along the plant periphery. Selection of plant species shall be as per the CPCB guidelines in consultation with the State Forest Department. Records of tree canopy shall be monitored through remote sensing map.
- (xvi) At least 2 % of the project cost of expansion shall be allocated for Corporate Environment Responsibility (CER), and shall be utilized for meeting requirement in the study area/public hearing issues. The CER plan shall be completed within three year of the expansion of the project.
- (xvii) A separate Environmental Management Cell (having qualified person with Environmental Science/Environmental Engineering/specialization in the project area) equipped with full-fledged laboratory facilities shall be set up to carry out the Environmental Management and Monitoring functions.
- **13.1** The grant of environmental clearance is further subject to compliance of other general conditions as under:-
  - (i) No further expansion or modifications in the plant, other than mentioned in the EIA Notification, 2006 and its amendments, shall be carried out without prior approval of the Ministry of Environment, Forest and Climate Change/SEIAA, as applicable. In case of deviations or alterations in the project proposal from those submitted to this Ministry for clearance, a fresh reference shall be made to the Ministry/SEIAA to assess the adequacy of conditions imposed and to add additional environmental protection measures required, if any.

EC for M/s Ajanta pharma Ltd

- (ii) The energy source for lighting purpose shall be preferably LED based, or advance having preference in energy conservation and environment betterment.
- (iii) The locations of ambient air quality monitoring stations shall be decided in consultation with the State Pollution Control Board (SPCB) and it shall be ensured that at least one station each is installed in the upwind and downwind direction as well as where maximum ground level concentrations are anticipated.
- (iv) The National Ambient Air Quality Emission Standards issued by the Ministry vide G.S.R. No. 826(E) dated 16<sup>th</sup> November, 2009 shall be followed.
- (v) The overall noise levels in and around the plant area shall be kept well within the standards by providing noise control measures including acoustic hoods, silencers, enclosures etc. on all sources of noise generation. The ambient noise levels shall conform to the standards prescribed under Environment (Protection) Act, 1986 Rules, 1989 viz. 75 dBA (day time) and 70 dBA (night time).
- (vi) The Company shall harvest rainwater from the roof tops of the buildings and storm water drains to recharge the ground water and to utilize the same for process requirements.
- (vii) Training shall be imparted to all employees on safety and health aspects of chemicals handling. Pre-employment and routine periodical medical examinations for all employees shall be undertaken on regular basis. Training to all employees on handling of chemicals shall be imparted.
- (viii) The company shall undertake all relevant measures for improving the socio-economic conditions of the surrounding area. CER activities shall be undertaken by involving local villages and administration and shall be implemented.
- (ix) The company shall undertake eco-developmental measures including community welfare measures in the project area for the overall improvement of the environment.
- (x) A separate Environmental Management Cell (having qualified person with Environmental Science/Environmental Engineering/specialization in the project area) equipped with full fledged laboratory facilities shall be set up to carry out the Environmental Management and Monitoring functions.
- (xi) The company shall earmark sufficient funds towards capital cost and recurring cost per annum to implement the conditions stipulated by the Ministry of Environment, Forest and Climate Change as well as the State Government along with the implementation schedule for all the conditions stipulated herein. The funds so earmarked for environment management/ pollution control measures shall not be diverted for any other purpose.
- (xii) A copy of the clearance letter shall be sent by the project proponent to concerned Panchayat, ZillaParishad/Municipal Corporation, Urban local Body and the local NGO, if any, from whom suggestions/ representations, if any, were received while processing the proposal.
- (xiii) The project proponent shall also submit six monthly reports on the status of compliance of the stipulated Environmental Clearance conditions including results of monitored data (both in hard copies as well as by e-mail) to the respective Regional Office of MoEF&CC, the respective Zonal Office of CPCB and SPCB. A copy of Environmental Clearance and six monthly compliance status report shall be posted on the website of the company.
- (xiv) The environmental statement for each financial year ending 31<sup>st</sup> March in Form-V as is mandated shall be submitted to the concerned State Pollution Control Board as Post M/s Ajanta pharma Ltd

  Page 11 of 13

prescribed under the Environment (Protection) Rules, 1986, as amended subsequently, shall also be put on the website of the company along with the status of compliance of environmental clearance conditions and shall also be sent to the respective Regional Offices of MoEF&CC by e-mail.

- (xv) The project proponent shall inform the public that the project has been accorded environmental clearance by the Ministry and copies of the clearance letter are available with the SPCB/Committee and may also be seen at Website of the Ministry and at https://parivesh.nic.in/. This shall be advertised within seven days from the date of issue of the clearance letter, at least in two local newspapers that are widely circulated in the region of which one shall be in the vernacular language of the locality concerned and a copy of the same shall be forwarded to the concerned Regional Office of the Ministry.
- (xvi) The project authorities shall inform the Regional Office as well as the Ministry, the date of financial closure and final approval of the project by the concerned authorities and the date of start of the project.
- (xvii) This Environmental clearance is granted subject to final outcome of Hon'ble Supreme Court of India, Hon'ble High Court, Hon'ble NGT and any other Court of Law, if any, as may be applicable to this project.
- The Ministry reserves the right to stipulate additional conditions, if found necessary at subsequent stages and the project proponent shall implement all the said conditions in a time bound manner. The Ministry may revoke or suspend the environmental clearance, if implementation of any of the above conditions is not found satisfactory.
- Concealing factual data or submission of false/fabricated and with conditions failure comply of to any the mentioned above may withdrawal this result in of clearance and attract action the provisions of the Environment (Protection) Act, 1986.
- Any appeal against this environmental clearance shall lie with the National Green Tribunal, if preferred, within a period of 30 days as prescribed under Section 16 of the National Green Tribunal Act, 2010.
- The above conditions shall be enforced, inter-alia under the provisions of the Water (Prevention & Control of Pollution) Act, 1974, the Air (Prevention & Control of Pollution) Act, 1981, the Environment (Protection) Act, 1986, Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016 and the Public Liability Insurance Act, 1991 along with their amendments and Rules and any other orders passed by the Hon'ble Supreme Court of India / High Courts and any other Court of Law relating to the subject matter. 110/2020

18. This issues with approval of the competent authority.

(Dr. R. B. Lal) Scientist E Additional Director

वैज्ञानिक 'ई'/Scientist 'E' पर्यावरण, वन एवं जलवायु परिवर्तन मंत्रालय Min. of Environment, Forest and Climate Change भारत सरकार, नई दिल्ली Govt. of India, New Delhi

## Copy to: -

- The Deputy DGF (C), MoEF&CC Regional Office(WCZ), Ground Floor, East Wing, New Secretariat Building, Civil Line, Nagpur - 1
- The Secretary, Environment Department, Government of Maharashtra, 15<sup>th</sup> Floor, New Administrative Building, Mantralaya, Mumbai - 32

- 3. The Member Secretary, Central Pollution Control Board, Parivesh Bhawan, CBD-cum-Office Complex, East Arjun Nagar, Delhi - 32
- 4. The Member Secretary, Maharashtra Pollution Control Board, Kalpataru Point, 3<sup>rd</sup> and 4<sup>th</sup> Floor, Opp. Cine Planet, Sion Circle, Mumbai 22
- 5. The District Collector, District Aurangabad (Maharashtra)
- 6. Guard File/Monitoring File/Website/Record File/Parivesh Portal

(Dr. R. B. Lal)

Scientist 'E'/Additional Director

Tele-fax: 011-24695362 Email-rb.lal@nic.in